Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial
Seong-Beom Park, Suryaprakash Mishra, Sang-Kyu Shin, Stebin Xavier, Giulia Zigon, Manuel Zocco, Marie Van Der Wielen, Dong-Gun Lee, on behalf of the AReSVi-006 study group · 2026
Read Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial by Seong-Beom Park, Suryaprakash Mishra, Sang-Kyu Shin, Stebin Xavier, Giulia Zigon, Manuel Zocco, Marie Van Der Wielen, Dong-Gun Lee, on behalf of the AReSVi-006 study group (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13655466.txt.
Description
Seong-Beom Park and co-authors report long-term results for an RSV vaccine in Korean older adults, in work from 2026. RSV, a common lung virus, poses a grave risk to older adults. A vaccine with an immune booster has shown strong protection in a world trial.
The Korean arm of that trial held 719 adults aged 60 and older at twelve sites. Half got one shot of the vaccine, and half got a dummy shot. This follow-up tracks immune levels for two years after the shot. It also logs side effects from days to six months out. Local data matter since response can vary by population. Results help Korean health planners judge a rollout.
Catalog record
| CREATOR | Seong-Beom Park, Suryaprakash Mishra, Sang-Kyu Shin, Stebin Xavier, Giulia Zigon, Manuel Zocco, Marie Van Der Wielen, Dong-Gun Lee, on behalf of the AReSVi-006 study group |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |